News


Pulmagen Therapeutics announces positive data for ADC3680, a once daily, orally administered CRTh2 antagonist in eosinophilic asthma patients in a 16-week Phase II study conducted in Japan by partner Teijin Pharma Limited

14th December 2016. Pulmagen Therapeutics (Asthma) Ltd announces positive data for PTR-36 (ADC3680), a once daily, orally administered CRTh2 antagonist in eosinophilic asthma patients in a 16-week Phase II double blind, placebo controlled study, that was conducted in Japan by Tokyo-based Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business. Pulmagen licensed its CRTh2 programme including PTR-36 for Japan to Teijin Pharma in 2012.

Pulmagen is to seek a global partner for late stage clinical development. Read the Press Release>>>

Skyepharma acquires a novel inhaled therapy platform SKP-2075, from Pulmagen Therapeutics to be developed as an anti-inflammatory treatment for COPD

13th August 2014. Skyepharma PLC (LSE SKP), the expert oral and inhalation drug delivery company, today announces that it has acquired the global rights and related intellectual property (including granted patents and patent applications) to a novel inhaled therapy platform from Pulmagen Therapeutics (Synergy) Limited.

Skyepharma will apply its proven expertise in inhaled drug development to develop a first product (SKP-2075) for chronic obstructive pulmonary disease (COPD) through to the completion of a phase II efficacy and safety trial sized to produce clinically significant data. It will then seek to out-licence SKP-2075 to a pharmaceutical partner for late-stage development and commercialisation.

Pulmagen’s lead CRTh2 antagonist, ADC3680, completes patient recruitment in Phase II study

1st August 2014. The efficacy of ADC3680 is currently being studied in a global Phase II clinical study in patients who remain symptomatic despite treatment with inhaled corticosteroids. Screening for this study which is being conducted at over 100 sites across the US and Europe has now completed and data will be reported in Q1 2015 (see [ClinicalTrials.Gov]). Pulmagen believes that ADC3680 is the only truly low dose (< 10mg), once daily, CRTh2 antagonist in clinical development and is positioned to be ‘best in class’ with the potential to be first to market.

Pulmagen presented on ADC3680 at ERS 2013 in Barcelona, 8th-12th September 2013

Pulmagen Therapeutics presented two posters on ADC3680, Pulmagen’s lead CRTh2 antagonist, at ERS 2013 in Barcelona on the 8th-12th September 2013. The investigational drug ADC3680, is a new chemical entity (NCE) being developed as a low dose, once daily oral CRTh2 antagonist suitable for use as a well-tolerated controller therapy in asthma. View the ERS Abstracts and Download the posters>>>

Pulmagen presented on ADC3680 at ATS 2013 in Philadelphia, 17th-22nd May 2013

Pulmagen Therapeutics presented two posters on ADC3680, Pulmagen’s lead CRTh2 antagonist, at ATS 2013 in Philadelphia on the 17th-22nd May 2013. The investigational drug ADC3680, is a new chemical entity (NCE) being developed as a low dose, once daily oral CRTh2 antagonist suitable for use as a well-tolerated controller therapy in asthma. View the ATS 2013 Abstracts>>>


Press Releases>>>